Dateline City:
KENILWORTH, N.J.
Results from C-EDGE CO-STAR Presented at The Liver Meeting Show High Sustained Virologic Response After 12 Weeks of Treatment
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the presentation of results from the companys Phase 3 C-EDGE
CO-STAR clinical trial evaluating the efficacy and safety of the
investigational once-daily tablet elbasvir/grazoprevir1
(50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes
(GT) 1, 4 or 6 infection who inject drugs and are receiving opioid
agonist therapy (OAT).
Language:
English
Contact:
MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more